Motley Fool Asset Management LLC Buys 48,999 Shares of DexCom, Inc. $DXCM

Motley Fool Asset Management LLC increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 24.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 249,215 shares of the medical device company’s stock after acquiring an additional 48,999 shares during the quarter. Motley Fool Asset Management LLC’s holdings in DexCom were worth $16,540,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Focus Partners Advisor Solutions LLC bought a new position in DexCom during the 4th quarter worth approximately $868,000. Advocacy Wealth Management LLC bought a new position in DexCom during the 4th quarter worth approximately $802,000. BLI Banque de Luxembourg Investments bought a new position in DexCom during the 4th quarter worth approximately $3,354,000. Cerity Partners LLC grew its position in DexCom by 14.6% during the 4th quarter. Cerity Partners LLC now owns 137,986 shares of the medical device company’s stock worth $9,159,000 after acquiring an additional 17,571 shares during the last quarter. Finally, Erste Asset Management GmbH grew its position in DexCom by 13.2% during the 4th quarter. Erste Asset Management GmbH now owns 28,259 shares of the medical device company’s stock worth $1,907,000 after acquiring an additional 3,287 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total value of $107,168.00. Following the completion of the transaction, the executive vice president owned 111,204 shares in the company, valued at $7,010,300.16. The trade was a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the completion of the sale, the director directly owned 25,007 shares of the company’s stock, valued at $1,500,670.07. The trade was a 3.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 42,694 shares of company stock worth $3,029,267 over the last three months. 0.28% of the stock is owned by corporate insiders.

DexCom Stock Up 2.0%

Shares of NASDAQ:DXCM opened at $78.19 on Wednesday. The stock has a fifty day simple moving average of $65.36 and a two-hundred day simple moving average of $67.28. The stock has a market capitalization of $30.17 billion, a price-to-earnings ratio of 33.41, a PEG ratio of 1.20 and a beta of 1.45. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. The business had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.32 earnings per share. On average, research analysts anticipate that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DXCM has been the topic of several recent research reports. Weiss Ratings restated a “hold (c-)” rating on shares of DexCom in a research report on Monday, June 1st. BTIG Research reiterated a “buy” rating and issued a $85.00 price objective on shares of DexCom in a research report on Monday, March 9th. Wells Fargo & Company cut their price objective on DexCom from $93.00 to $85.00 and set an “overweight” rating on the stock in a research report on Friday, February 13th. TD Cowen cut their price objective on DexCom from $84.00 to $75.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Finally, Citigroup reiterated a “buy” rating and issued a $84.00 price objective (up from $79.00) on shares of DexCom in a research report on Thursday, May 28th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus price target of $83.46.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.